PL3710485T3 - Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania - Google Patents

Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania

Info

Publication number
PL3710485T3
PL3710485T3 PL19732174T PL19732174T PL3710485T3 PL 3710485 T3 PL3710485 T3 PL 3710485T3 PL 19732174 T PL19732174 T PL 19732174T PL 19732174 T PL19732174 T PL 19732174T PL 3710485 T3 PL3710485 T3 PL 3710485T3
Authority
PL
Poland
Prior art keywords
sez6
application
antibody conjugates
conjugates
antibody
Prior art date
Application number
PL19732174T
Other languages
English (en)
Inventor
David Liu
Julia Gavrilyuk
Alexander SCHAMMEL
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of PL3710485T3 publication Critical patent/PL3710485T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19732174T 2018-05-30 2019-05-30 Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania PL3710485T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862678061P 2018-05-30 2018-05-30
PCT/US2019/034701 WO2019232241A1 (en) 2018-05-30 2019-05-30 Anti-sez6 antibody drug conjugates and methods of use
EP19732174.8A EP3710485B8 (en) 2018-05-30 2019-05-30 Anti-sez6 antibody drug conjugates and methods of use

Publications (1)

Publication Number Publication Date
PL3710485T3 true PL3710485T3 (pl) 2021-09-13

Family

ID=66998493

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19732174T PL3710485T3 (pl) 2018-05-30 2019-05-30 Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania

Country Status (32)

Country Link
US (4) US20210196834A1 (pl)
EP (2) EP3710485B8 (pl)
JP (1) JP6936399B2 (pl)
KR (1) KR20210018316A (pl)
CN (1) CN112135843A (pl)
AU (1) AU2019278870A1 (pl)
BR (1) BR112020024223A2 (pl)
CA (1) CA3097199A1 (pl)
CL (1) CL2020003044A1 (pl)
CO (1) CO2020016151A2 (pl)
CR (1) CR20200623A (pl)
CY (1) CY1124183T1 (pl)
DK (1) DK3710485T3 (pl)
EC (1) ECSP20082970A (pl)
ES (1) ES2867148T3 (pl)
HR (1) HRP20210631T1 (pl)
HU (1) HUE053616T2 (pl)
IL (1) IL278225A (pl)
LT (1) LT3710485T (pl)
MA (1) MA51453A (pl)
MX (1) MX2020012788A (pl)
NZ (1) NZ768778A (pl)
PE (1) PE20211497A1 (pl)
PH (1) PH12020551968A1 (pl)
PL (1) PL3710485T3 (pl)
PT (1) PT3710485T (pl)
RS (1) RS61770B1 (pl)
RU (1) RU2770474C1 (pl)
SG (1) SG11202011576VA (pl)
SI (1) SI3710485T1 (pl)
SM (1) SMT202100368T1 (pl)
WO (1) WO2019232241A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240117A1 (ko) 2021-05-10 2022-11-17 강원대학교 산학협력단 항체 결합 재조합 융합 단백질 및 이를 이용한 항체-약물 접합체
KR102819556B1 (ko) 2021-05-10 2025-06-13 강원대학교산학협력단 항체 결합 재조합 융합 단백질 및 이를 이용한 항체-약물 접합체
CA3264543A1 (en) * 2022-08-26 2024-02-29 Abbvie Inc. ANTIBODY-DRUG ANTI-ATTACK CONJUGATES RELATED TO 6 HOMOLOGUES
AU2024270504A1 (en) 2023-05-08 2025-11-27 Changzhou Hansoh Pharmaceutical Co., Ltd. Antibody or antigen-binding fragment thereof, antibody-drug conjugate, and use thereof
WO2025167503A1 (en) * 2024-02-05 2025-08-14 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-sez6/b7h3 antibodies and uses thereof
CN120365421B (zh) * 2025-04-24 2025-11-04 成都古格尔生物技术有限公司 一种特异性抗sez6靶点的全人源抗体及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
PL224001B1 (pl) * 2002-05-02 2016-11-30 Wyeth Corp Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
SG10201506959SA (en) 2010-09-03 2015-10-29 Stemcentrx Inc Novel modulators and methods of use
SG11201405130UA (en) * 2012-02-24 2014-11-27 Stemcentrx Inc Anti sez6 antibodies and methods of use
WO2015003154A1 (en) 2013-07-03 2015-01-08 Histosonics, Inc. Articulating arm limiter for cavitational ultrasound therapy system
MX377339B (es) 2013-08-28 2025-03-06 Abbvie Stemcentrx Llc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones.
KR20160046914A (ko) * 2013-08-28 2016-04-29 스템센트알엑스 인코포레이티드 신규한 ｓｅｚ6 조절물질 및 사용방법
MA41645A (fr) * 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
CN107849146A (zh) * 2015-04-21 2018-03-27 艾伯维施特姆森特克斯有限责任公司 卡奇霉素构建体和使用方法
JP2019506847A (ja) * 2015-12-22 2019-03-14 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｍｍｐ１６抗体及び使用方法
JP2019526529A (ja) * 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート

Also Published As

Publication number Publication date
CN112135843A (zh) 2020-12-25
JP6936399B2 (ja) 2021-09-15
CR20200623A (es) 2021-07-01
JP2021508694A (ja) 2021-03-11
US20210196834A1 (en) 2021-07-01
CA3097199A1 (en) 2019-12-05
KR20210018316A (ko) 2021-02-17
SG11202011576VA (en) 2020-12-30
WO2019232241A1 (en) 2019-12-05
US20250213714A1 (en) 2025-07-03
US20210338831A1 (en) 2021-11-04
PE20211497A1 (es) 2021-08-11
RS61770B1 (sr) 2021-05-31
RU2770474C1 (ru) 2022-04-18
SMT202100368T1 (it) 2021-07-12
EP3710485B8 (en) 2021-06-23
MX2020012788A (es) 2021-02-15
MA51453A (fr) 2020-09-23
CO2020016151A2 (es) 2021-05-31
PT3710485T (pt) 2021-05-04
DK3710485T3 (da) 2021-05-10
AU2019278870A1 (en) 2020-10-29
US11077203B2 (en) 2021-08-03
EP3710485B1 (en) 2021-03-31
NZ768778A (en) 2022-07-01
CY1124183T1 (el) 2022-05-27
SI3710485T1 (sl) 2021-08-31
EP3858863A1 (en) 2021-08-04
ES2867148T3 (es) 2021-10-20
ECSP20082970A (es) 2021-01-29
BR112020024223A2 (pt) 2021-03-16
LT3710485T (lt) 2021-05-10
IL278225A (en) 2020-11-30
US20200316215A1 (en) 2020-10-08
HRP20210631T1 (hr) 2021-05-28
PH12020551968A1 (en) 2021-09-13
HUE053616T2 (hu) 2021-07-28
EP3710485A1 (en) 2020-09-23
CL2020003044A1 (es) 2021-04-16

Similar Documents

Publication Publication Date Title
IL286291A (en) Compounds and conjugates thereof
IL279897A (en) Fusosome compositions and uses thereof
IL284276A (en) Saponin conjugates
PL3626825T3 (pl) Przeciwciało anty-cdh6 i koniugat przeciwciała anty-cdh6 z lekiem
EP3807644A4 (en) ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
HUE065882T2 (hu) Interleukin-2-polipeptid-konjugátumok és alkalmazásaik
PL3383916T3 (pl) Przeciwciała anty-cd73 i ich zastosowania
DK3592393T3 (da) Frigørbare konjugater
DK3579883T3 (da) Pyrrolobenzodiazepin-antistofkonjugater
PL3515487T3 (pl) Dwuswoiste przeciwciała anty-muc16-cd3 oraz koniugaty przeciwciało anty-muc16 - lek
DK3458479T3 (da) Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
PL3313884T3 (pl) Przeciwciała anty-cd123 oraz ich koniugaty i pochodne
PL3423105T3 (pl) Koniugaty przeciwciało-lek oparte na erybulinie i sposoby zastosowania
PL3618928T3 (pl) Przeciwciała antysortylinowe i sposoby ich stosowania
PL3280441T3 (pl) Przeciwciała przeciwko sortilinie i sposoby ich stosowania
IL278122B1 (en) Pteridinone compounds and uses thereof
LT3544636T (lt) Pirolobenzodiazepino-antikūno konjugatai
IL270595B1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MA47468A (fr) Anticorps anti-ilt3 et conjugués anticorps-médicament
IL291179A (en) Cnp variants and conjugates thereof
EP3612567C0 (en) ANTI-VTCN1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
PL3710485T3 (pl) Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania
EP3638697A4 (en) ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
DK3668874T3 (da) Pyrrolobenzodiazepin-konjugater
IL283942A (en) Tubulysins and protein-tubulysin conjugates